The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Midatech Doses First Patients In MTD201 Administration Method Study

Tue, 08th Oct 2019 11:34

(Alliance News) - Midatech Pharma PLC on Tuesday said a phase one study of MTD201 as a treatment for acromegaly and neuroendocrine tumours has begun.

The goal of the study is to assess subcutaneous administration as an additional injection route versus intramuscular administration.

Acromelagy is hormone disorder which can cause bones in the hands, feet, and face to get bigger. Neuroendocrine tumours affect the cells responsible for releasing hormones.

A previous 2018 study already found that MTD201 had a better long-acting clinical profile when administered as a intramuscular injection compared to Novartis AG's drug Sandostatin. This dosing method study will decide which method of administration will be used in Midatech's pivotal registration study starting 2020.

The first cohort of healthy volunteers in this newer study have been dosed, being 14 of the 28 subjects. The cohort all received one dose of Sandostatin on Friday last week, followed by either a subcutaneous or intramuscular dose of MTD201 on Monday this week.

The other 14 subjects will experience the same procedure later this week, which will complete the study's dosing phase. All subjects will be observed for 63 days before data is analysed. Top line results are due by 2019 end or early 2020.

Shares in Midatech were up 2.2% at 6.26 pence in London late on Tuesday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Related Shares

More News
24 Mar 2023 18:17

IN BRIEF: Midatech Pharma delisting and name change approved

Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Says resolutio...

17 Mar 2023 15:42

UK shareholder meetings calendar - next 7 days

15 Feb 2023 10:35

Midatech Pharma shares up as closed USD6.0 million private placement

(Alliance News) - Midatech Pharma PLC on Wednesday said it has raised USD6.0 million through a private placement of 10.3 million shares at USD0.58 eac...

9 Feb 2023 20:25

IN BRIEF: Midatech Pharma raises USD6.0 million for clinical asset

Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Raises gross p...

3 Feb 2023 11:42

Midatech's Nasdaq price falls below minimum of USD1.00 per share

(Alliance News) - Midatech Pharma PLC on Friday said it received notice that its share price has fallen short of the minimum needed according to Nasda...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.